Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > No-one has access to ONCY's manufacturing process

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Feb 08, 2023 7:09pm

141 Views

Post# 35275864

RE:RE:RE:RE:RE:No-one has access to ONCY's manufacturing process

No need bickering with each other boys and girls. I think most of us are on the same side, and want little more than to see Onc succeed & BP get Pela to market. The interminable blackout & the SP getting pounded into oblivion certainly contributes to the frayed nerves.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023